Market Drivers: Key drivers include increasing prevalence of immunodeficiency disorders globally, rising demand for plasma-derived medicinal products, and a growing geriatric population. The market ...

Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

Learn more about whether Exact Sciences Corporation or Grifols, S.A. is a better investment based on AAII's A+ Investor ...

Learn more about whether Alkermes plc or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which ...

The A/G ratio is a blood test that measures levels of albumin and globulin, the two main proteins in your blood. A high albumin-to-globulin (A/G) ratio may indicate kidney disease, an antibody ...

For example, Grifols has announced plans to increase ... especially in immune globulins and albumin derivatives. The market for rare and specialized plasma-derived therapies is expected to grow ...

Factor IX Concentrate: This product is vital for treating hemophilia B, contributing to about 15% of market share. Albumin: Commonly used in critical care settings and for liver diseases, albumin ...

Adding albumin to total nutrient admixtures (TNAs) or three-in-one solutions cannot be recommended because of stability concerns; it has been shown to cause creaming in as little as 4 hours.

Based on the available evidence, the addition of albumin to PN solutions cannot be recommended. The potential for complications due to infection and physical and chemical incompatibility and ...

Industry Major Player: Grifols S.A. Grifols S.A ... such as Recombinant Human Serum Albumin rHSA Albumin-based therapy innovations, like the development of recombinant human serum albumin rHSA ...